BIT 8.11% 4.0¢ biotron limited

$10 Billion Deal, page-12434

  1. 7,602 Posts.
    lightbulb Created with Sketch. 959

    Hepatitis C Market Forecast 2032: FDA, EMA, PDMA Approvals, Epidemiology, Therapies, Clinical Trials and Companies by DelveInsight | BMS, Merck, Roche, Gilead Sciences, Johnson & Johnson, Abbvie

    https://www.theglobeandmail.com/investing/markets/markets-news/GetNews/26038163/hepatitis-c-market-forecast-2032-fda-ema-pdma-approvals-epidemiology-therapies-clinical-trials-and-companies-by-delveinsight-bms-merck-roche-gilead-sciences-johnson-johnson-abbvie/
 
watchlist Created with Sketch. Add BIT (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.